No Data
No Data
H.C. Wainwright Downgrades Carisma Therapeutics(CARM.US) to Hold Rating
Express News | HC Wainwright & Co. Downgrades CARISMA Therapeutics to Neutral
Carisma Downgraded by Baird Over Lack of Near-term Catalysts
Express News | D. Boral Capital Maintains Buy on CARISMA Therapeutics, Maintains $12 Price Target
Carisma Therapeutics Price Target Cut to $1.00/Share From $10.00 by Baird
Baird Downgrades Carisma Therapeutics(CARM.US) to Hold Rating, Cuts Target Price to $1
Unlock the Full List